◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › SYK

Stryker Corporation (SYK) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Health Care Equipment · DATA UPDATED 2026-07-12

Stryker Corporation (SYK) operates in the Health Care Equipment industry and is headquartered in Portage, United States with about 56,000 employees. Its market capitalization is roughly $127 billion. In the fiscal year ended 2025-12-31, SYK reported $25.1B in revenue and $3.2B in net income.

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics.

Interactive charts & full statements → Open the SYK valuation workbench →

SYK Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-03-312025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Revenue$25.3B$25.1B$22.6B$20.5B$18.4B$17.1B$14.4B$14.9B$13.6B$12.4B$11.3B$9.9B$9.7B$9.0B$8.7B$8.3B$7.3B$6.7B$6.7B$6.0B$5.4B
Gross Profit$16.1B$16.1B$14.0B$12.5B$11.0B$10.7B$8.8B$9.4B$8.6B$7.9B$7.2B$6.4B$6.2B$5.9B$5.8B$5.5B$5.0B$4.5B$4.5B$4.1B$3.5B
Gross Margin %63.7%64.0%61.9%61.0%59.8%62.6%61.0%63.0%63.2%63.5%64.0%64.2%64.3%65.9%66.7%66.4%68.0%67.0%67.7%68.2%65.0%
Operating Income (EBIT)$5.4B$4.9B$5.1B$4.3B$3.7B$3.8B$3.0B$3.4B$3.1B$2.8B$2.6B$2.3B$2.2B$2.1B$1.9B$2.0B$1.9B$1.7B$1.6B$1.3B$1.1B
Operating Margin %21.3%19.5%22.4%20.9%20.2%22.0%21.1%22.8%22.8%22.2%22.8%22.6%23.0%23.3%22.1%23.7%25.3%25.6%23.1%22.1%20.8%
Net Income$3.3B$3.2B$3.0B$3.2B$2.4B$2.0B$1.6B$2.1B$3.6B$1.0B$1.6B$1.4B$515M$1.0B$1.3B$1.3B$1.3B$1.1B$1.1B$1.0B$778M
Net Margin %13.2%12.9%13.2%15.4%12.8%11.7%11.1%14.0%26.1%8.2%14.5%14.5%5.3%11.2%15.0%16.2%17.4%16.5%17.1%17.0%14.4%
EBITDA$6.2B$6.3B$4.9B$5.1B$4.0B$3.6B$3.1B$3.6B$3.3B$3.0B$2.7B$2.2B$1.7B$1.6B$2.0B$2.3B$2.2B$2.0B$2.0B$1.8B$1.4B
Earnings Per Share (EPS)$8.63$8.49$7.76$8.25$6.17$5.22$4.20$5.48$9.34$2.68$4.35$3.78$1.35$2.63$3.39$3.45$3.19$2.77$2.78$2.44$1.89
Shares Outstanding (M)386M382M386M384M382M382M380M380M380M380M378M381M383M382M383M390M400M399M414M417M411M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SYK Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue$6.0B$7.2B$6.1B$6.0B$5.9B$6.4B$5.5B$5.4B
Gross Profit$3.8B$4.7B$3.9B$3.8B$3.7B$4.0B$3.4B$3.3B
Gross Margin %63.3%65.2%63.6%62.3%62.7%62.0%61.8%61.3%
Operating Income (EBIT)$936M$2.0B$1.1B$1.4B$1.2B$1.7B$1.2B$1.2B
Operating Margin %15.6%27.4%18.7%22.6%20.1%25.8%22.0%21.4%
Net Income$745M$849M$859M$884M$654M$546M$834M$825M
Net Margin %12.4%11.8%14.2%14.7%11.2%8.5%15.2%15.2%
EBITDA$1.3B$2.0B$1.4B$1.5B$1.0B$792M$1.3B$1.3B
Earnings Per Share (EPS)$1.93$2.20$2.22$2.29$1.69$1.41$2.16$2.14
Shares Outstanding (M)386M386M387M386M386M386M386M385M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SYK Free Cash Flow History

Cash flowTTM → 2026-03-312025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Cash from Operations (CFO)$5.4B$5.0B$4.2B$3.7B$2.6B$3.3B$3.3B$2.2B$2.6B$1.6B$1.9B$899M$1.8B$1.9B$1.7B$1.4B$1.5B$1.5B$1.2B$1.0B$867M
Capital Expenditures (CapEx)$804M$761M$755M$575M$588M$525M$487M$649M$572M$598M$490M$270M$233M$195M$210M$226M$182M$131M$155M$188M$218M
Free Cash Flow (FCF)$4.6B$4.3B$3.5B$3.1B$2.0B$2.7B$2.8B$1.5B$2.0B$961M$1.4B$629M$1.5B$1.7B$1.4B$1.2B$1.4B$1.3B$1.0B$841M$650M
FCF Margin %18.1%17.1%15.4%15.3%11.0%16.0%19.4%10.4%15.0%7.7%12.6%6.3%16.0%18.8%16.7%14.5%18.6%19.8%15.2%14.0%12.0%
Dividends Paid$1.3B$1.3B$1.2B$1.1B$1.1B$950M$863M$778M$703M$636M$568M$521M$462M$401M$324M$279M$238M$198M$136M$90M$45M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SYK Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Cash from Operations (CFO)$581M$2.1B$1.5B$1.1B$250M$1.9B$1.5B$633M
Capital Expenditures (CapEx)$166M$268M$187M$183M$123M$266M$170M$152M
Free Cash Flow (FCF)$415M$1.9B$1.4B$928M$127M$1.7B$1.3B$481M
FCF Margin %6.9%26.2%22.3%15.4%2.2%25.9%23.7%8.9%
Dividends Paid$337M$321M$322M$321M$320M$305M$305M$305M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SYK Balance Sheet History

Balance sheet2026-03-312025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Assets$46.3B$47.8B$43.0B$39.9B$36.9B$34.6B$34.3B$30.2B$27.2B$22.2B$20.4B$16.2B$17.7B$15.7B$13.5B$12.4B$10.9B$9.1B$7.6B$7.4B$5.9B
Cash & Cash Equivalents$2.9B$4.0B$3.7B$3.0B$1.8B$2.9B$2.9B$4.3B$3.6B$2.5B$3.3B$3.4B$1.8B$1.3B$1.4B$905M$1.8B$659M$701M$290M$417M
Total Liabilities$23.3B$25.4B$22.3B$21.3B$20.3B$19.8B$21.2B$17.4B$15.5B$12.2B$10.9B$7.7B$9.1B$6.7B$4.9B$4.7B$3.7B$2.5B$2.2B$2.0B$1.7B
Total Debt (Short + Long-Term)$14.9B$16.0B$13.6B$13.1B$13.2B$12.5B$14.0B$11.1B$9.9B$7.2B$6.9B$4.0B$4.0B$2.8B$1.8B$1.8B$1.0B$18M$20M$17M$15M
Total Shareholders' Equity$23.0B$22.4B$20.6B$18.6B$16.6B$14.9B$13.1B$12.8B$11.7B$10.0B$9.6B$8.5B$8.6B$9.0B$8.6B$7.7B$7.2B$6.6B$5.4B$5.4B$4.2B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SYK viewer.

Other Companies in Health Care Equipment

← SYFAll stocksSYM →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.